证券代码：600161 证券简称：天坛生物 公告编号：2024-021 北京天坛生物制品股份有限公司 关于所属企业药品临床试验进展公告 | 产品 | | 获得临床试验批 | | 注册 | 剂 | 研发 | | --- | --- | --- | --- | --- | --- | --- | | | 适应症 | 准通知书时间和 | 规格 | | | 投入 | | 名称 | | | | 分类 | 型 | | | | | 编号 | | | | | | | 本品适用于血友病A患者 | | | | | | | 注射用重 | 出血的控制和预防。 | 2023 年 12 月 19 | | | | | | 组人凝血 | 本品适用于血友病A患者 | | 250IU/瓶 | 治疗用 | 注 | 6290.97 | | 因 子Ⅷ- | 的手术出血预防。 | 日 | | 生物制 | 射 | | | | | 2023LP02596 ， | 1000IU/瓶 | | | 万元 | | Fc 融合蛋 | 本品不适用于治疗血管性 | 2023LP02597 | | 品 | 剂 | | | 白 | 血友病（ von Willebrand | ...

证券代码：600161 证券简称：天坛生物 公告编号：2024-020 北京天坛生物制品股份有限公司 关于召开 2023 年度业绩暨现金分红说明会公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 4 月 23 日(星期二)10:00-11:30 三、 参加人员 公司董事总经理付道兴先生、独立董事方燕女士、财务总监王虹青先生、董事 会秘书慈翔女士等。（如有特殊情况，参会人员将可能进行调整） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 16 日(星期二)至 4 月 22 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 ttswdb@sinopharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 一、 说明会类型 北京天坛生物制品 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [4][11]. Core Insights - The company achieved a revenue of 5.18 billion yuan in 2023, representing a year-on-year growth of 21.57%, and a net profit attributable to shareholders of 1.11 billion yuan, up 25.99% year-on-year [6][9]. - The company continues to lead in plasma collection and blood product revenue, with a significant increase in plasma collection volume by 18.67% to 2,415 tons in 2023 [6][10]. - New products have been launched, including the fourth-generation 10% concentration intravenous immunoglobulin, which is the first of its kind approved in China [10][11]. Financial Performance - The company reported a gross margin of 50.76% in 2023, an increase of 1.68 percentage points year-on-year, and a net profit margin of 29.14%, up 0.87 percentage points year-on-year [11]. - The operating cash flow net amount reached 2.394 billion yuan, a significant increase of 112.57% year-on-year [9][10]. - For 2024-2026, the expected earnings per share (EPS) are projected to be 0.66 yuan, 0.78 yuan, and 0.92 yuan, with corresponding price-to-earnings (PE) ratios of 39.2, 33.0, and 28.2 respectively [6][11]. Market Position and Growth Prospects - The company is expected to maintain stable growth in its blood products business due to continuous increases in plasma collection and the gradual market release of new products [6][10]. - The company has made significant progress in project advancements and capacity layout, with multiple production facilities now operational [10][11]. - The company has strengthened its R&D capabilities, achieving breakthroughs in new product development and maintaining a leading position in the industry [10][11].

2024年4月11日 公司研究 业绩超预期，静丙高景气度持续拉动增长 ——天坛生物（600161.SH）2024 年一季度业绩快报点评 要点 增持（维持） 当 前价：25.81元 事件：公司发布2024年第一季度业绩快报，实现营业收入12.22亿元，同比 -5.42%；归母净利润3.17亿元，同比+20.91%；扣非归母净利润3.13亿元，同 比+23.82%；EPS（基本）0.19元。业绩超市场预期。 作者 分析师：王明瑞 点评： 执业证书编号：S0930520080004 021-52523867 产品价格、成本费用等因素推动利润好转，静丙高景气度持续拉动增长：2024 wangmingrui@ebscn.com 年一季度营业收入下滑，主要是销售量相比去年同期有小幅下降；利润同比增长， 主要是产品价格、成本费用管控等因素的推动。血制品板块仍然维持高景气度， 静丙终端需求非常旺盛，成为拉动公司业绩增长的重要驱动因素。 市场数据 管理层增持彰显信心，“提质增效重回报”强化核心竞争力：公司自2023年9 总股本(亿股) 16.48 总市值(亿元)： 425.30 月1日起的增持计划已经于2024年3月1日实施完 ...

证券代码：600161 证券简称：天坛生物 公告编号：2024-018 北京天坛生物制品股份有限公司 关于所属企业获得药品补充申请批准通知书并通过药品 GMP 符合性检查公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司所属成都蓉生药业有限责任公司（以下简称"成都蓉 生"）于近日收到国家药品监督管理局签发的《药品补充申请批准通知书》，成都蓉生研制 的"人纤维蛋白原"符合药品注册的相关要求。同时，成都蓉生相关生产场地已通过药品 GMP 符合性检查，并获得了四川省药品监督管理局签发的《药品 GMP 现场检查结果通知书》 （川 2022105）。具体情况如下： 一、 概况 （一） 产品信息 *注：上述国内市场情况来自国家药品监督管理局官方网站（http://www.nmpa.gov.cn）。 二、 《药品 GMP 现场检查结果通知书》主要内容 企业名称：成都蓉生药业有限责任公司 药品生产许可证编号：川 20160165 检查地址：四川省成都市双流区菁园路 280 号 检查范围：血液制品（人纤维蛋白原） ...

Investment Rating - The report maintains a "Buy" rating for Tiantan Biological (600161) [1] Core Views - The company achieved a revenue of 5.18 billion yuan in 2023, representing a year-on-year growth of 21.6%, and a net profit attributable to shareholders of 1.11 billion yuan, up 26% year-on-year [3] - The fourth quarter showed some fluctuations in performance, with quarterly revenues of 1.29 billion, 1.4 billion, 1.33 billion, and 1.16 billion yuan, reflecting a growth of 83.3%, 18%, 30.2%, and a decline of 14.1% respectively [3] - The company collected 2,415 tons of plasma in 2023, exceeding expectations with an 18.7% year-on-year increase [3] - The report forecasts net profits for 2024, 2025, and 2026 to be 1.3 billion, 1.49 billion, and 1.77 billion yuan respectively, supported by rich plasma station resources and new product approvals [3] Summary by Sections Financial Performance - In 2023, the company reported a total revenue of 5,180 million yuan with a growth rate of 21.57% [4] - The net profit attributable to shareholders was 1,109.89 million yuan, reflecting a growth rate of 25.98% [4] - The average revenue per quarter showed significant variation, with the fourth quarter experiencing a decline of 20.6% in net profit compared to the previous quarter [3] Plasma Collection and Operations - The company operated 79 plasma collection stations by the end of 2023, with a total of 102 approved stations [3][9] - The average plasma collection per station was 30.6 tons, with expectations for continued growth as new stations become operational [3] Future Projections - Revenue projections for 2024 to 2026 are estimated at 5,913 million, 7,012 million, and 8,407 million yuan respectively, with growth rates of 14.15%, 18.57%, and 19.90% [4] - The report anticipates a steady increase in net profit, with growth rates of 16.81%, 14.56%, and 19.49% for the same period [4] Market Position and Strategy - The company is focusing on expanding its blood source development and enhancing operational efficiency through various measures [3] - The report highlights the importance of new product approvals and the expansion of plasma collection capabilities as key drivers for future growth [3]

证券代码：600161 证券简称：天坛生物 公告编号：2024-017 北京天坛生物制品股份有限公司 关于所属企业获得药物临床试验批准通知书公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京天坛生物制品股份有限公司所属国药集团武汉生物制药有限公司 获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意国药集团武 汉生物制药有限公司开展"人凝血酶原复合物"临床试验。现将有关信息披露如 下： 一、概况 （一） 产品信息 | 产品 | | 适应症 | 获得受理的时 | 规格 | 注册分类 | 剂型 | 研发 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | 间及受理号 | | | | 投入 | | | | 本品主要用于治疗先天性和获得性 | | | | | | | | | 凝血因子II、VII、IX和X缺乏症（单 | | | | | | | | | 独或联合缺陷）包括： | | | | | | | | | 1.凝血因子II、VII、IX和 ...

Investment Rating - The report maintains an "Overweight" rating for the company [1] Core Insights - The company achieved a revenue of 5.18 billion yuan in 2023, representing a year-over-year growth of 21.57%, and a net profit of 1.11 billion yuan, which is a 25.98% increase year-over-year [4][9] - The demand for blood products, particularly immunoglobulin, has significantly increased due to the lifting of pandemic restrictions, leading to a notable rise in sales [4][9] - The company has a leading position in plasma collection, with a total collection of 2,415 tons in 2023, marking an 18.67% increase [17] Financial Performance Summary - Revenue and Profit Forecast: - 2024E revenue is projected at 6.18 billion yuan, with a growth rate of 19.28% - Net profit for 2024E is expected to be 1.33 billion yuan, reflecting a year-over-year growth of 19.64% [5] - Key Financial Metrics: - Earnings per share (EPS) is forecasted to increase from 0.67 yuan in 2023 to 0.81 yuan in 2024 - The price-to-earnings (P/E) ratio is expected to decrease from 39.79 in 2023 to 33.26 in 2024 [1][5] Operational Highlights - The company has maintained stable expense ratios, with sales expenses increasing by 3.22% to 271 million yuan, while the sales expense ratio decreased by 0.93 percentage points to 5.22% [13] - The company has expanded its plasma collection stations to 79, with plans for 22 more under construction, enhancing its operational capacity [17] - Cash flow from operations has significantly improved due to increased sales and changes in credit policies, leading to higher cash collections [13]

上 市 公 司 医药生物 2024 年04月 01 日 天坛生物 (600161) 公 司 研 究 ——采浆量持续增长，产品线优化升级 公 司 点 报告原因：有业绩公布需要点评 评 买入 投资要点： （维持）  事件：天坛生物发布 2023年年报，2023年公司实现收入 51.80亿（同比+21.57%）， 实现归母净利润 11.10 亿（同比+25.99%），实现扣非归母净利润 11.04 亿（同比 证 市场数据： 2024年03月29日 +29.35%）；单 Q4实现收入 11.58 亿元（同比-14.11%），实现归母净利润 2.22亿元 券 收盘价（元） 27.03 研 一年内最高/最低（元） 32.73/23 （同比-20.56%），实现扣非归母净利润2.25亿元（同比-17.07%）。业绩符合预期。 究 市净率 4.5 报 息率（分红/股价） -  产品格局优化，采浆持续增长。2023 年公司人血白蛋白实现收入 22.47 亿元（同比 告 流通A股市值（百万元） 44540 +17.88%），静注人免疫球蛋白实现收入23.19亿元（同比+16.89%），其他血液制品实 上证指数/深证成指 30 ...

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company achieved a revenue of 51.8 billion yuan in 2023, representing a year-on-year growth of 21.6%. The net profit attributable to shareholders was 11.1 billion yuan, up 26.0% year-on-year [1]. - The sales of blood products saw rapid growth, with the main products' gross margins improving. Human albumin revenue reached 22.5 billion yuan, a 17.9% increase, with a gross margin of 48.7%, up 2.5 percentage points. Immunoglobulin revenue was 23.2 billion yuan, a 16.9% increase, with a gross margin of 50.4%, up 2.6 percentage points [1]. - The company collected 2415 tons of plasma in 2023, an 18.67% increase year-on-year, maintaining a leading position in the domestic market [1]. - The company has established three new production bases with a total capacity of 3600 tons, enhancing its production scale and design capacity [1]. - New products are expected to contribute to growth, with a rich pipeline of products under development, including a fourth-generation immunoglobulin and recombinant coagulation factor VIII [1]. Financial Summary - The company forecasts revenues of 59.99 billion yuan in 2024, 69.59 billion yuan in 2025, and 80.02 billion yuan in 2026, with growth rates of 15.81%, 16.00%, and 14.98% respectively [2]. - The net profit attributable to shareholders is projected to be 13.05 billion yuan in 2024, 15.42 billion yuan in 2025, and 18.12 billion yuan in 2026, with growth rates of 17.60%, 18.13%, and 17.52% respectively [2]. - The gross margin is expected to improve from 50.76% in 2023 to 53.03% in 2026 [2]. - The diluted EPS is projected to increase from 0.67 yuan in 2023 to 1.10 yuan in 2026 [2]. Additional Insights - The company has a strong pipeline with over ten products under development, focusing on rare diseases and immune deficiencies [1]. - The company’s PE ratio is projected to decrease from 40.13 in 2023 to 24.58 in 2026, indicating potential value for investors [2].